VOR - NASDAQ
Vor Biopharma Inc.
$13.44
-0.037%Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotVor Biopharma Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Vor Biopharma Inc. Cash Flow Statement
VOR • NASDAQ
| Vor Biopharma Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-696M | -116.9M | -117.9M | -92.1M | -68.9M | -43.3M | -10.8M | -4.2M | |
2.9M | 3.5M | 3.5M | 2.5M | 1.4M | 605K | 91K | 20K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -32K | 289K | |
18.9M | 9.8M | 13.4M | 10.7M | 4.3M | 1.3M | 172K | 116K | |
521.3M | 3.9M | 67K | 6.4M | 3.2M | 782K | 608K | 1M | |
10.2M | 5K | 650K | -12.7M | -9.2M | 4.3M | 145K | 63K | |
-142.7M | -99.7M | -100.3M | -85.1M | -69.1M | -36.3M | -9.9M | -2.7M | |
INVESTING ACTIVITIES | ||||||||
-941K | -229K | -1.1M | -8.5M | -3.9M | -4.2M | -748K | (0.0) | |
-53.7M | -9.9M | -74.9M | -123.2M | -87.8M | (0.0) | (0.0) | (0.0) | |
5M | 107M | 147M | 37.6M | 0.0 | 0.0 | 0.0 | 0.0 | |
799K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-48.8M | (96.9M) | (71M) | -94.1M | -91.7M | -4.2M | -748K | (0.0) | |
FINANCING ACTIVITIES | ||||||||
505.1M | 55.8M | 4.6M | 116M | 189.2M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.5M | |
-1.3M | -2.4M | -1.6M | 1.2M | -1.7M | 259K | 7K | 0.0 | |
503.8M | 53.4M | 2.9M | 117.1M | 232.9M | 82.5M | 17.7M | 2.5M | |
CASH FLOW SUMMARY | ||||||||
312.3M | 50.6M | -26.3M | -62.1M | 72.1M | 42.1M | 7.1M | -197K | |
84.4M | 33.8M | 60.1M | 122.2M | 50.1M | 8M | 929K | 1.1M | |
396.7M | 84.4M | 33.8M | 60.1M | 122.2M | 50.1M | 8M | 929K | |
-143.7M | -99.9M | -101.4M | -93.6M | -73M | -40.5M | -10.6M | -2.7M |
SEC Filings
VOR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
S-3 S-3 N/A | April 27, 2026 | April 27, 2026 | ||
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | April 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 26, 2026 | 2026 | |
S-3 S-3 N/A | January 29, 2026 | January 29, 2026 | ||
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 15, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 09, 2025 | December 05, 2025 | 2025 |
Related Guides
Continue your VOR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.